ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronEye IconIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintSite TitleTitle ChevronIcon Twitter
Health Technology

Chugai Pharmaceutical Co., Ltd.

Business Summary

Chugai Pharmaceutical Co., Ltd. engages in the research, development, manufacturing, sale, importation, and exportation of the pharmaceuticals. Its operations are carried out through the following business divisions: Research, Development, Production, Marketing, Medical Affairs and Drug Safety. The Research division focuses its efforts on creating innovative drugs by using its competitive strengths that include proprietary antibody technologies and cutting-edge research resources. The Development division provides cross-functional lifecycle management system to deliver innovative medicines to patients as quickly as possible. The Production division provides a world-class safety and quality management systems. The Marketing division conducts patient-oriented marketing activities to help solve issues related to healthcare. The Medical Affairs division works to properly deliver the value of medicines based on global compliance standards. The Drug Safety provides safety management system includes expert safety evaluation as well as timely gathering and reporting of safety information. The company was founded by Juzo Ueno on March 10, 1925 and is headquartered in Tokyo, Japan.

Financial Highlights

Dec 2019 JPYUSD
Gross Profit419,922M3,852.11M
Operating income214,513M1,967.81M
Income before tax207,893M1,907.08M
Net income157,560M1,445.36M
Diluted EPS95.800.87
Dividends Per Share46.660.42
Total Assets1,058.91B9,743.86M
Total liabilities204,929M1,885.70M
Total equity853,985M7,858.15M
Operating cash flow206,811M1,897.16M
Currency in JPYCurrency in USD

Historical Data

 Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019
Revenue 498,839M 491,780M 534,199M 579,787M 686,184M
Gross Profit 258,523M 243,553M 279,574M 316,025M 419,922M
Operating income 88,838M 79,320M 102,973M 129,225M 214,513M
Income before tax 87,276M 74,448M 97,031M 121,449M 207,893M
Net income 61,125M 53,592M 72,714M 92,488M 157,560M
EBITDA 104,405M 95,689M 119,307M 145,803M 240,914M
Diluted EPS 37.26 32.65 44.27 56.26 95.80
Dividends Per Share 19.33 17.33 20.66 28.66 46.66
Total Assets 787,401M 806,285M 852,473M 919,548M 1,058.91B
Total liabilities 160,130M 159,789M 159,576M 163,020M 204,929M
Total equity 625,857M 645,508M 691,924M 755,865M 853,985M
Operating cash flow 63,266M 39,080M 107,889M 119,269M 206,811M
 Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019
Revenue 4,120.42M 4,525.90M 4,763.94M 5,249.65M 6,294.64M
Gross Profit 2,135.40M 2,241.44M 2,493.22M 2,861.43M 3,852.11M
Operating income 733.80M 729.99M 918.30M 1,170.06M 1,967.81M
Income before tax 720.90M 685.15M 865.31M 1,099.65M 1,907.08M
Net income 504.89M 493.21M 648.45M 837.42M 1,445.36M
EBITDA 862.38M 880.63M 1,063.97M 1,320.16M 2,210.00M
Diluted EPS 0.30 0.30 0.39 0.50 0.87
Dividends Per Share 0.15 0.15 0.18 0.25 0.42
Total Assets 6,545.58M 6,912.89M 7,567.44M 8,381.24M 9,743.86M
Total liabilities 1,331.14M 1,369.99M 1,416.56M 1,485.84M 1,885.70M
Total equity 5,202.68M 5,534.42M 6,142.24M 6,889.34M 7,858.15M
Operating cash flow 522.57M 359.65M 962.14M 1,079.91M 1,897.16M

Valuation Measures

Dec 2019
Operating margin31.26%
Profit margin22.96%

Key executives

  • Chairman & Chief Executive Officer: Tatsuro Kosaka
  • President, COO & Representative Director: Osamu Okuda
  • CFO, Manager-Information Technology & Accounting: Itagaki Toshiaki
  • Executive Officer & GM-Clinical Development: Hisanori Takanashi
  • Senior Executive Officer & Head-Research: Hisafumi Okabe


  • Roche Holding AG (59.8%)
  • Nomura Asset Management Co., Ltd. (2.9%)
  • Capital Research & Management Co. (World Investors) (2.4%)
  • Chugai Pharmaceutical Co., Ltd. (2.1%)
  • Wellington Management Co. LLP (1.6%)
  • Nikko Asset Management Co., Ltd. (1.4%)
  • Daiwa Asset Management Co. Ltd. (1.4%)
  • The Vanguard Group, Inc. (1.1%)
  • Capital Research & Management Co. (Global Investors) (0.9%)
  • BlackRock Fund Advisors (0.8%)

Contact Details

  • Website:
  • Address: Nihonbashi Mitsui Tower, 15/F, 2-1-1 Nihonbashi-Muromachi, Tokyo, 103-8324, Japan
  • Phone: +81.3.3281.6611

Related Companies

  • Chugai Distribution Co., Ltd.
  • Medical Culture YK
  • Chugai Business Support Co., Ltd.
  • Chugai Clinical Research Center Co., Ltd.
  • Chugai Pharma Technology Taizhou Co., Ltd.
  • Chugai Pharmaceutical Restricted Stock Compensation Plan
  • Chugai Pharma Consulting (Shanghai) Co., Ltd.
  • Chugai Pharma R&D Taiwan Ltd.
  • Chugai Pharma China Co., Ltd.
  • Chugai Pharma Science (Beijing) Co., Ltd.
  • Chugai Pharma Taiwan Ltd.
  • Chugai Pharmabody Research Pte Ltd.
  • Pharmalogicals Research Pte Ltd.
  • Forerunner Pharma Research Co., Ltd.
  • Chugai Research Institute for Medical Science, Inc.
  • Chugai Pharma Manufacturing Co., Ltd.
  • Chugai Pharmaceutical Employee Stock Ownership Plan
  • Chugai Pharma U.K. Ltd.
  • Chugai Pharma France SAS
  • Chugai USA, Inc.
  • Chugai Biopharmaceuticals, Inc.
  • Chugai Pharma USA LLC
  • Nippon Roche KK


  • Regeneron Pharmaceuticals, Inc.
  • Harpoon Therapeutics, Inc.
  • BioCryst Pharmaceuticals, Inc.
  • Cara Therapeutics Inc
  • Viela Bio, Inc.
  • Ascendis Pharma A/S Sponsored ADR
  • Alexion Pharmaceuticals, Inc.
  • Springworks Therapeutics, Inc.
  • Unum Therapeutics, Inc.
  • Kiniksa Pharmaceuticals Ltd. Class A
  • InflaRx N.V.
Last Updated on 7 Aug, 2020

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Try 1 month for $0.99

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends July 31st

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to the Nikkei Asian Review has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media